15 Although a meta-analysis of randomized clinical trials found that rosiglitazone was not associated with a significant modification of cancer risk, epidemiologic data regarding individual

sites of cancer risk associated with different TZDs were inconsistent. 16-20 Therefore, the objective of this study was to conduct a nested case-control study based on a nation-wide health insurance claims database in Taiwan to assess BGB324 nmr the association between TZDs (both pioglitazone and rosiglitazone) and the occurrences of liver, colorectal, lung, and urinary bladder cancers. DDD, defined daily dose; PPAR, peroxisome proliferator-activated receptor; TZD, thiazolidinedione. The Taiwan National Health Insurance (NHI) claims database includes complete outpatient visits, hospital admissions, prescriptions, disease, and vital status for 99% of the population of 23 million in Taiwan. We established the longitudinal medical history of each beneficiary by linking selleck products several computerized administrative and claims datasets to National Cancer and Death Registry through the date of birth and the civil identification number unique to each beneficiary. The protocol of this study was approved by the National Taiwan University Hospital Research Ethics Committee. Data for all patients with any diabetes diagnostic codes (International Classification

of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), ICD-9-CM code 250 and A code 181) in the claims database between January 1 2000 and December 31 2000 were retrieved. An algorithm including age, number of outpatient visits, number of hospitalizations, and the hospital level was used to identify potential diabetic patients with improved accuracy. This definition of

diabetes was evaluated by a study sampling 9,000 patients with a diagnosis ADAMTS5 of diabetes in the NHI claims data in 2000. The diagnostic accuracy of diabetes was assessed based on patient response to a questionnaire concerning (1) being told by doctors they have diabetes or (2) ever use of oral hypoglycemic agents or insulin injections. Subjects who gave negative or uncertain answers but were using hypoglycemic agents in the pharmacy claims database were also classified as diabetic. Validation of this algorithm by which 640,173 patients were identified demonstrated 93.2% sensitivity and 92.3% positive predictive value. Because diabetic patients may receive highly variable antidiabetic therapies in terms of drug regimens, dosage, duration, and other concomitant drugs, and confounding factors are constantly changing over time in a long-term observational follow-up study, there are complex analytical difficulties for a cohort analysis to be attempted. Instead, a nested case-control approach is a useful alternative of cohort analysis to study time-dependent exposures. 21 The risk estimates from cohort and nested case-control analyses should be identical if confounding is fully controlled in both analyses.